Thrombocythemia Myelofibrosis
Showing 1 - 25 of 412
Assess the Safety of Fedratinib in Korean Myelofibrosis
Recruiting
- Primary Myelofibrosis
- +2 more
-
Seoul, Korea, Republic ofBristol-Myers Squibb YH
Oct 3, 2023
Myelofibrosis (PMF), Post Essential Thrombocythemia Myelofibrosis (ET-MF), Post Polycythemia Vera Related Myelofibrosis (PV-MF)
Not yet recruiting
- Myelofibrosis (PMF)
- +2 more
-
New York, New YorkRuttenberg Treatment Center
Apr 18, 2023
Myeloproliferative Tumor, Polycythemia Vera, Essential Thrombocythemia Trial in Hong Kong
Recruiting
- Myeloproliferative Neoplasm
- +7 more
-
Hong Kong, Hong KongDepartment of Medicine, Queen Mary Hospital
May 21, 2023
Primary Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, ET-MF Trial in New York (Canakinumab)
Recruiting
- Primary Myelofibrosis
- +4 more
-
New York, New YorkRuttenberg Treatment Center
Jul 18, 2022
Primary Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Post-polycythemia Vera Myelofibrosis Trial in Ipoh (NS-018,
Recruiting
- Primary Myelofibrosis
- +2 more
- NS-018
- Best Available Therapy
-
Worcester, Massachusetts
- +16 more
Oct 31, 2022
Myelofibrosis Trial in Canton (Jaktinib Hydrochloride Tablet)
Recruiting
- Myelofibrosis
- Jaktinib Hydrochloride Tablet
-
Canton, OhioSite 01
Aug 18, 2022
Myelofibrosis Due to and Following Polycythemia Vera Trial in United States (Ruxolitinib, Abemaciclib)
Recruiting
- Myelofibrosis Due to and Following Polycythemia Vera
-
Basking Ridge, New Jersey
- +6 more
Jan 26, 2023
A Prospective, Two-arm, Non-interventional Study of JAKAVIĀ® in
Active, not recruiting
- Primary Myelofibrosis
- +2 more
- Jakavi
-
Aachen, GermanyNovartis Investigative Site
Sep 6, 2021
Idiopathic Myelofibrosis, Post Essential Thrombocythemia Myelofibrosis, Post Polycythemia-Vera Myelofibrosis Trial in Worldwide
Completed
- Idiopathic Myelofibrosis
- +2 more
-
Paris, France
- +9 more
Jun 22, 2021
Myelodysplastic/Myeloproliferative Tumor, Unclassifiable, Myelofibrosis Transformation in Essential Thrombocythemia,
Recruiting
- Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable
- +3 more
- Azacitidine
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Aug 18, 2022
Polycythemia Vera, Essential Thrombocythemia, and
Not yet recruiting
- Myeloproliferative Neoplasm
- Next-generation sequencing
- (no location specified)
Jun 27, 2022
Myeloproliferative Disorders, Essential Thrombocythemia, Tumors Trial (JNJ-88549968)
Not yet recruiting
- Myeloproliferative Disorders
- +3 more
- (no location specified)
Nov 21, 2023
Myeloproliferative Tumor, Essential Thrombocythemia, Primary Myelofibrosis, Prefibrotic Stage Trial (CALR allele burden
Recruiting
- Myeloproliferative Neoplasm
- +3 more
- CALR allele burden quantification
-
Angers, FranceCHU Angers
Nov 2, 2022
Myeloproliferative Tumor, MPN, Essential Thrombocythemia Trial in Orange (N-Acetylcysteine)
Active, not recruiting
- Myeloproliferative Neoplasm
- +4 more
-
Orange, CaliforniaChao Family Comprehensive Cancer Center, University of Californi
Jan 6, 2023
Myelofibrosis, Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis Trial in Hangzhou (Jaktinib HCl tablets)
Recruiting
- Myelofibrosis
- +3 more
- Jaktinib hydrochloride tablets
-
Hangzhou, Zhejiang, ChinaThe First Affiliated Hospital of Medical School of Zhejiang Univ
Jun 11, 2021
Myelofibrosis, Polycythemia Vera, Thrombocythemia Trial in Worldwide (itacitinib)
Active, not recruiting
- Myelofibrosis
- +2 more
-
New Orleans, Louisiana
- +20 more
Aug 25, 2022